Published in J Bone Miner Res on January 01, 2004
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone (2010) 1.41
Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer (2006) 1.05
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? BMC Cancer (2006) 1.00
Relationship between serum RANKL and RANKL in bone. Osteoporos Int (2011) 0.94
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med (2013) 0.92
Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am (2008) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
CXC chemokine ligand 16 in periodontal diseases: expression in diseased tissues and production by cytokine-stimulated human gingival fibroblasts. Clin Exp Immunol (2007) 0.87
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int (2011) 0.86
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. J Bone Miner Metab (2005) 0.85
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther (2008) 0.84
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. Skeletal Radiol (2007) 0.84
Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int (2009) 0.82
Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm (2011) 0.82
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? Osteoporos Int (2005) 0.81
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses (2006) 0.80
Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm (2014) 0.79
Passage-affected competitive regulation of osteoprotegerin synthesis and the receptor activator of nuclear factor-kappaB ligand mRNA expression in normal human osteoblasts stimulated by the application of cyclic tensile strain. J Bone Miner Metab (2009) 0.79
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab (2009) 0.77
Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporos Int (2008) 0.76
Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. J Bone Miner Metab (2014) 0.76
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab (2007) 0.75
Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep (2015) 0.75
Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats. Med Oral Patol Oral Cir Bucal (2017) 0.75
Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid. BMC Immunol (2016) 0.75
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci (2003) 4.10
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73
miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61
A new social communication intervention for children with autism: pilot randomised controlled treatment study suggesting effectiveness. J Child Psychol Psychiatry (2004) 2.59
A global perspective on trends in nature-based tourism. PLoS Biol (2009) 2.58
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells (2008) 2.39
Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res (2013) 2.25
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A (2002) 2.24
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One (2011) 2.10
A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev (2007) 1.96
Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med (2005) 1.86
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood (2005) 1.80
Diversity of noroviruses cocirculating in the north of England from 1998 to 2001. J Clin Microbiol (2004) 1.65
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol (2009) 1.64
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood (2004) 1.57
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
The conceptualization and measurement of therapeutic alliance: an empirical review. Clin Psychol Rev (2008) 1.56
Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol (2011) 1.55
Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone (2007) 1.52
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care (2014) 1.48
Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther (2007) 1.47
TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells (2009) 1.47
Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol (2012) 1.47
RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43
Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res (2005) 1.40
TWEAK is a novel arthritogenic mediator. J Immunol (2006) 1.37
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res (2006) 1.33
Public health value of next-generation DNA sequencing of enterohemorrhagic Escherichia coli isolates from an outbreak. J Clin Microbiol (2012) 1.31
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One (2011) 1.31
Long-term imatinib therapy promotes bone formation in CML patients. Blood (2007) 1.30
Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain (2002) 1.27
Quality of interaction between at-risk infants and caregiver at 12-15 months is associated with 3-year autism outcome. J Child Psychol Psychiatry (2012) 1.27
Dysregulation of bone remodeling by imatinib mesylate. Blood (2009) 1.26
Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis (2002) 1.26
Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells (2009) 1.24
Parent-infant interaction in infant siblings at risk of autism. Res Dev Disabil (2012) 1.22
Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20
Genomic profiling of mesenchymal stem cells. Stem Cell Rev (2009) 1.20
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res (2009) 1.18
Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am (2007) 1.16
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr (2010) 1.15
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer (2002) 1.11
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol (2007) 1.10
Molecular epidemiology of rotaviral infection in South Indian children with acute diarrhea from 1995-1996 to 1998-1999. J Med Virol (2002) 1.10
Motivational interviewing: a pilot test of active ingredients and mechanisms of change. Psychol Addict Behav (2012) 1.08
The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials (2004) 1.07
The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone (2004) 1.06
Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology (2010) 1.04
Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics (2013) 1.03
Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am J Respir Cell Mol Biol (2003) 1.03
An exploratory study of the association between reactive attachment disorder and attachment narratives in early school-age children. J Child Psychol Psychiatry (2009) 1.03
The impact of maternal psychopathology on child-mother attachment. Arch Womens Ment Health (2009) 1.02
Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomater (2011) 1.02
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res (2010) 1.02
The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials (2009) 1.01
The use of OP-1 in femoral impaction grafting in a sheep model. J Orthop Res (2004) 1.01
2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem (2007) 1.01
Service and wider societal costs of very young children with autism in the UK. J Autism Dev Disord (2012) 1.01
Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res (2009) 1.00
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther (2009) 1.00
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res (2010) 1.00
Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend (2008) 1.00
Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat (2009) 0.99
CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Lab Invest (2003) 0.98
Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells (2015) 0.97
UNIVERSAL VERSUS ECONOMICALLY POLARIZED CHANGE IN AGE AT FIRST BIRTH: A FRENCH-BRITISH COMPARISON. Popul Dev Rev (2009) 0.97
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone (2004) 0.97
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica (2009) 0.97
Primary human osteoblasts grow into porous tantalum and maintain an osteoblastic phenotype. J Biomed Mater Res A (2008) 0.97